[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SK281249B6 - (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom - Google Patents

(-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom Download PDF

Info

Publication number
SK281249B6
SK281249B6 SK1257-93A SK125793A SK281249B6 SK 281249 B6 SK281249 B6 SK 281249B6 SK 125793 A SK125793 A SK 125793A SK 281249 B6 SK281249 B6 SK 281249B6
Authority
SK
Slovakia
Prior art keywords
crystalline form
oxathiolan
cis
amino
hydroxymethyl
Prior art date
Application number
SK1257-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK125793A3 (en
Inventor
Paul Ravenscroft
Tony Gordon Roberts
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK281249(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SK125793A3 publication Critical patent/SK125793A3/sk
Publication of SK281249B6 publication Critical patent/SK281249B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Medicinal Preparation (AREA)
SK1257-93A 1991-06-03 1992-06-02 (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom SK281249B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds
PCT/EP1992/001213 WO1992021676A1 (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives

Publications (2)

Publication Number Publication Date
SK125793A3 SK125793A3 (en) 1994-11-09
SK281249B6 true SK281249B6 (sk) 2001-01-18

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1257-93A SK281249B6 (sk) 1991-06-03 1992-06-02 (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom

Country Status (31)

Country Link
US (1) US5905082A (is)
EP (2) EP0517145B1 (is)
JP (1) JP2851480B2 (is)
KR (1) KR100244008B1 (is)
AP (1) AP300A (is)
AT (1) ATE212630T1 (is)
AU (2) AU656379B2 (is)
BG (1) BG60914B1 (is)
CA (2) CA2070230C (is)
CZ (1) CZ284513B6 (is)
DE (1) DE69232387T2 (is)
DK (1) DK0517145T3 (is)
ES (1) ES2171158T3 (is)
GB (1) GB9111902D0 (is)
GE (1) GEP19991834B (is)
HK (1) HK1009599A1 (is)
IE (2) IE20020782A1 (is)
IL (1) IL102073A (is)
IS (2) IS1867B (is)
MX (1) MX9202619A (is)
NO (1) NO301713B1 (is)
NZ (1) NZ242981A (is)
OA (1) OA09913A (is)
PT (1) PT517145E (is)
RU (1) RU2102393C1 (is)
SG (1) SG52455A1 (is)
SK (1) SK281249B6 (is)
TW (1) TW254939B (is)
UA (1) UA41265C2 (is)
WO (1) WO1992021676A1 (is)
ZA (1) ZA924007B (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
EP1655033A1 (en) 1995-06-07 2006-05-10 Emory University Nucleosides with anti-hepatitis B virus activity
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
EP0938321B1 (en) 1996-06-25 2004-01-14 Glaxo Group Limited Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
DK1389207T3 (da) * 2001-03-01 2006-04-18 Gilead Sciences Inc Polymorfe og andre krystallinske former af cis-FTC
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
CA2505130C (en) * 2002-11-08 2009-10-06 Glaxo Group Limited Pharmaceutical compositions
CN105596356A (zh) * 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
AU2005304486B2 (en) * 2004-11-10 2011-08-11 Novartis Vaccines And Diagnostics Inc. Deamidated interferon-beta
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
AU2007237818B2 (en) * 2006-04-18 2012-09-27 Lupin Limited A novel crystalline form of lamivudine
WO2009031026A2 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel pharmaceutical compositions
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
BRPI0820222A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Forma i cristalina estável de lamivudina e processo de preparação
EP2225232B1 (en) * 2007-11-29 2012-09-26 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
CN101918416A (zh) * 2007-11-29 2010-12-15 兰贝克赛实验室有限公司 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
US8536151B2 (en) * 2008-09-01 2013-09-17 Hetero Research Foundation Process for preparing lamivudine polymorph form
EP2350065A1 (en) * 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
EP2435052B1 (en) * 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
WO2011007367A1 (en) 2009-07-15 2011-01-20 Lupin Limited An improved process for preparation of efavirenz
ES2540074T3 (es) 2009-10-14 2015-07-08 Mylan Laboratories Limited Proceso para la preparación de lamivudina y nuevas sales en la fabricación de la misma
MA34002B1 (fr) 2010-01-27 2013-02-01 Glaxosmithkline Llc Thérapie antivirale
US20120295930A1 (en) * 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
JP2013519676A (ja) * 2010-02-12 2013-05-30 メルク・シャープ・エンド・ドーム・コーポレイション ラミブジン形態ｉの調製
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
EP2739620A1 (en) 2011-08-05 2014-06-11 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides

Also Published As

Publication number Publication date
NO301713B1 (no) 1997-12-01
ES2171158T3 (es) 2002-09-01
BG60914B1 (bg) 1996-06-28
IS1867B (is) 2003-05-02
AP300A (en) 1994-01-20
IE921780A1 (en) 1992-12-16
CA2070230A1 (en) 1992-12-04
IL102073A0 (en) 1993-01-14
NZ242981A (en) 1994-04-27
US5905082A (en) 1999-05-18
DK0517145T3 (da) 2002-05-06
IS3873A (is) 1992-12-04
IS4268A (is) 1995-02-27
AU1736192A (en) 1993-03-11
DE69232387D1 (de) 2002-03-14
AU1881092A (en) 1993-01-08
JP2851480B2 (ja) 1999-01-27
IL102073A (en) 1996-05-14
EP1099700A1 (en) 2001-05-16
MX9202619A (es) 1992-12-01
TW254939B (is) 1995-08-21
SG52455A1 (en) 1998-09-28
CZ284513B6 (cs) 1998-12-16
GEP19991834B (en) 1999-11-05
CA2311988C (en) 2005-11-15
PT517145E (pt) 2002-07-31
NO922182D0 (no) 1992-06-02
RU2102393C1 (ru) 1998-01-20
EP0517145B1 (en) 2002-01-30
DE69232387T2 (de) 2002-09-26
WO1992021676A1 (en) 1992-12-10
CZ261293A3 (en) 1994-04-13
IE20020782A1 (en) 2003-04-02
CA2311988A1 (en) 1992-12-04
HK1009599A1 (en) 1999-06-04
SK125793A3 (en) 1994-11-09
CA2070230C (en) 2004-08-03
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
OA09913A (en) 1994-09-15
NO922182L (no) 1992-12-04
JPH06211848A (ja) 1994-08-02
KR930000511A (ko) 1993-01-15
BG98254A (bg) 1994-07-29
KR100244008B1 (ko) 2000-03-02
UA41265C2 (uk) 2001-09-17
ZA924007B (en) 1993-04-28
EP0517145A1 (en) 1992-12-09
GB9111902D0 (en) 1991-07-24
AU656379B2 (en) 1995-02-02

Similar Documents

Publication Publication Date Title
SK281249B6 (sk) (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom
IE83503B1 (en) Crystalline oxathiolane derivatives
SK391091A3 (en) Crystalline paroxetine hydrochloride hemihydrate, pharmacuetical composition containing the same and its use
BG60679B1 (bg) Аналози на 1,3-оксатиоланнуклеозида
AU2008331168A1 (en) Crystalline form I of lamivudine and its preparation
HU221808B1 (hu) Spikamicinszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1727798A1 (de) Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
KR100453301B1 (ko) 1-트리플루오로메틸-4-히드록시-7-피페리디닐-아미노메틸크로만 유도체
WO2022009863A1 (ja) ベンゾイソキサゾール誘導体
Bambury et al. Mesoionic pyridazine ribonucleosides. A novel biologically active nucleoside metabolite
RU2252211C2 (ru) Ароматические дикетопроизводные, способы получения и применение данных соединений в качестве фармацевтических средств
CN113527395B (zh) 一种腺苷的晶型及其制备方法
WO2003027106A1 (en) Process for the preparation of crystalline polymorph ii of lamivudine
EP0456514B1 (en) 2-Fluoroneplanocin A and its production
CZ2015824A3 (cs) Krystalická forma Canagliflozinu a způsob její přípravy
JP2006232671A (ja) 新規セレナゾリン誘導体
CN117466908A (zh) 腺苷受体抑制剂的晶体形式及其制备方法和用途
JPS62270527A (ja) ４１８１−２物質及びその誘導体を有効成分とする抗腫瘍剤
CN112851640A (zh) 嘧啶苯甲酰胺化合物的硫酸盐及其用途
JP2001218595A (ja) 光学活性シクロヘキセン誘導体の製造法およびその合成中間体

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20120602